Dextrol

Quick links to important sections

Dextrol

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Dextrol

Understanding Dextrol

Dextrol is an anticholinergic medication primarily used in the management of overactive bladder (OAB). It belongs to a class of drugs known as antimuscarinics, which work by affecting the muscles of the bladder.

Mechanism of Action

The active component in Dextrol acts as a competitive antagonist at muscarinic receptors. These receptors are located on the surface of bladder muscle cells and are responsible for triggering contractions. By binding to these receptors, the medication helps to decrease the urgency and frequency of bladder contractions, leading to an increase in the volume of urine the bladder can hold.

Clinical Applications

Dextrol is typically prescribed to address symptoms associated with bladder instability, including:

  • Urinary Urgency: A sudden, strong need to urinate that is difficult to delay.
  • Urinary Frequency: The need to urinate more often than usual during a 24-hour period.
  • Urge Incontinence: The involuntary loss of urine following a strong sense of urgency.

Therapeutic Goal

The primary objective of treatment with Dextrol is to improve the quality of life for individuals experiencing bladder control issues. By stabilizing the detrusor muscle (the smooth muscle of the bladder wall), the medication helps restore a more predictable and manageable urinary pattern.

Regulatory References

  1. MedlinePlus Drug Information

What side effects are possible with Dextrol?

Dextrol’s safety profile is formally documented by government regulatory bodies using a system that classifies adverse reactions by the part of the body affected and their reported frequency.

Adverse Reactions by Frequency and Body System

Adverse reactions are classified according to incidence observed in clinical studies:

  • Very Common (ge 1/10): Includes effects such as nausea and vomiting.
  • Uncommon (ge 1/1,000 to < 1/100): Includes events such as severe cerebral edema.

The most commonly reported adverse reactions are often linked to a flu-like syndrome, which is typically most prominent at the start of treatment and generally decreases in frequency with continued use.

Side effects are also grouped by System-Organ Class, including Gastrointestinal disorders, Respiratory, thoracic and mediastinal disorders, and Blood and lymphatic system disorders.

Serious Adverse Reactions and Key Safety Concerns

The regulatory safety documentation highlights several serious adverse reactions and important identified risks, including:

  • Respiratory: Rare pulmonary undesirable effects have been reported, such as interstitial pneumonia, pulmonary edema, and pulmonary infiltrates, which can potentially lead to respiratory failure or Adult Respiratory Distress Syndrome (ARDS).
  • Vascular/Hematologic: Serious events documented include pulmonary embolism and thrombocytopoenia.
  • Immunologic: Severe hypersensitivity reactions require the immediate discontinuation of the medicine.

Safety Considerations

The official safety profile notes that patients with a recent history of pulmonary infiltrates or pneumonia may be at a higher risk for rare pulmonary problems. Due to the risk of thrombocytopoenia, close monitoring of hematological parameters (e.g., platelet count) is required. Additionally, close monitoring for signs of pulmonary toxicity is necessary, particularly in the early phase of treatment.

Overdose and Emergency Response

The official regulatory profile for Dextrol overdose details specific manifestations of anticholinergic toxicity. Documented symptoms may include confusion, dry mouth, micturition difficulties (urinary retention), and visual impairments such as mydriasis (pupil dilation) and accommodation disturbances. More severe outcomes involve documented central anticholinergic effects like hallucinations and severe excitation. The overdose profile also notes cardiovascular risks, including tachycardia and the potential for an increase in the QT interval at supratherapeutic doses, along with severe neurological and respiratory issues such as convulsions and respiratory insufficiency.

Emergency Actions and Management

Regulators strictly require seeking immediate medical attention for any suspected overdose. Emergency services must be contacted immediately if the patient collapses, experiences a seizure, exhibits trouble breathing, or cannot be awakened. Initial management procedures officially described include gastric lavage and the administration of activated charcoal. Physostigmine is specified as the recommended agent for treating severe central anticholinergic effects. Treatment is symptomatic and supportive, involving specific measures for documented effects, such as using benzodiazepines for pronounced excitation and beta-blockers for tachycardia. Standard supportive measures are required for managing QT prolongation in a hospital setting.

Therapeutic Uses of Dextrol

Quick Facts

  • Primary Use: Management of symptoms associated with overactive bladder (OAB).
  • Benefits Include: May help reduce the occurrence of urge urinary incontinence, urgency, and urinary frequency.

What Dextrol Treats: Main Uses and Benefits

Dextrol is a prescription treatment indicated for the management of overactive bladder (OAB) in adult patients. Overactive bladder is a common condition associated with a group of symptoms that can affect quality of life. The medication is used to help manage these symptoms, which may include urge urinary incontinence, urgency, and frequent urination.

The therapeutic goal of Dextrol is to assist in reducing the incidence of these urinary episodes. Use of the medication is intended to help improve bladder function and support the management of daily activities for individuals with OAB. The treatment is part of a broader care plan that should be discussed with a healthcare provider.

Before considering any treatment, patients should consult with a healthcare professional to understand its approved indications and safety profile.

Eligibility and Restrictions for Use

Who can and cannot use Dextrol?

The eligibility for Dextrol (Tolterodine) is determined by regulatory agencies and is based on documented patient status and pre-existing medical conditions.

Populations Excluded from Use (Contraindications)

Patients must not use Dextrol if they have any of the following conditions, as stated in official labeling:

  • Urinary Retention: An inability to empty the bladder.
  • Gastric Retention: Significantly delayed or slow emptying of the stomach.
  • Uncontrolled Narrow-Angle Glaucoma: An eye condition that can be worsened by this medicine.
  • Hypersensitivity: A known allergy to Tolterodine tartrate or any component of the formulation.

Age-Related Eligibility

Age Group Official Status
Adults (18+ years) Approved and Indicated
Pediatric Population Not Recommended; efficacy and safety not established by the FDA.

Conditional Eligibility (Requires Caution/Restriction)

Use of Dextrol may be limited or require careful medical evaluation for patients with certain conditions, including:

  • Severe Hepatic Impairment (Severe liver problems).
  • Severe Renal Impairment (Severe kidney problems, specifically CrCl <10 mL/min is not recommended).
  • Myasthenia Gravis or risk factors for QT prolongation.

Pregnancy and Lactation Status

Use during pregnancy is classified as Category C by the FDA, meaning it should only be used if the potential benefit justifies the potential risk. It is not known if Dextrol is excreted into human milk, and caution is advised during breastfeeding.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Dextrol is subject to significant drug interactions, primarily due to its metabolism by cytochrome P450 enzymes, specifically CYP2D6 and to a lesser extent CYP3A4. Co-administration with medicinal products that inhibit these enzymes can substantially increase the concentration of Dextrol in the blood, leading to a greater potential for adverse effects.

Clinically Significant Interacting Product Categories

Interaction Classification Interacting Product Category Restriction and Basis
Contraindicated Monoamine Oxidase Inhibitors (MAOIs) Must not be used concurrently or within 14 days of stopping an MAOI due to the risk of Serotonin Syndrome.
High Alert Serotonergic Drugs (e.g., SSRIs, TCAs, Triptans) Increased risk of Serotonin Syndrome; requires dose reduction and/or close clinical monitoring.
High Alert CYP2D6 and CYP3A4 Inhibitors (e.g., fluoxetine, quinidine, ketoconazole) Increases Dextrol exposure; concurrent use is restricted or requires significant monitoring.
Caution CNS Depressants (e.g., alcohol, narcotic analgesics) Additive depressant effects may occur, which requires patient caution regarding driving or operating machinery.

Official Interaction-Related Restrictions

The regulatory profile explicitly mandates a washout period of at least 14 days between stopping an MAOI and starting Dextrol. The concomitant use of Dextrol with other serotonergic agents requires careful evaluation and is sometimes restricted. Specific CYP2D6 inhibitors such as quinidine are listed as agents that can increase Dextrol's systemic exposure and necessitate caution or dose adjustment. The product's overall interaction structure is defined by the high regulatory emphasis placed on preventing Serotonin Syndrome and managing increased exposure from metabolic inhibition.

Mechanism of Action

Dextrol (Tolterodine) functions by competitively antagonizing muscarinic receptors within the parasympathetic nervous system. Its action is centered on inhibiting the primary neurotransmitter involved in contraction, resulting in an increase in the functional storage volume.


Targeted Blockade of Muscarinic Acetylcholine Receptors

Dextrol and its active metabolite, 5-hydroxymethyl Tolterodine (5-HM), competitively block muscarinic acetylcholine receptors (M-receptors), primarily on the surface of the detrusor muscle. This mechanism directly interrupts the excitatory signals sent by the parasympathetic nervous system, preventing Acetylcholine (ACh) from binding and initiating the muscle contraction cascade.


Inhibition of Involuntary Detrusor Contraction

The functional consequence of blocking the M-receptors is the suppression of involuntary detrusor muscle contractions. This reduction in muscle spasm and tone allows the bladder wall to relax, resulting in a physiological effect that includes an increase in the functional storage capacity and a corresponding elevation of the volume threshold needed to trigger the reflex to void.

Dosage and Administration Information

How to Use Dextrol

Dextrol, which contains the active ingredient tolterodine tartrate, is administered to adult patients via the oral route for the management of overactive bladder symptoms. The drug is available in two formulations, each with a specific dosing schedule and administration method.


Dosing Patterns and Frequency

The required dosing frequency is determined by the specific form used:

Dosage Form Standard Adult Dose Frequency Maximum Daily Dose
IR Tablet (1 mg, 2 mg) 2 mg Twice Daily 4 mg
ER Capsule (2 mg, 4 mg) 4 mg Once Daily 4 mg

The immediate-release (IR) dose may be reduced to 1 mg twice daily, and the extended-release (ER) dose may be lowered to 2 mg once daily, based on patient response.


Administration Conditions

Both the IR tablets and ER capsules can be taken with or without food. For the extended-release capsule, the official instruction is that it must be swallowed whole with water and should not be crushed, chewed, or opened, as this would compromise its controlled-release mechanism. If a dose is missed, the patient should take it as soon as possible, unless it is nearly time for the next scheduled dose, in which case the missed dose should be skipped.

Population-Specific Use

Official instructions mandate dose reductions for certain populations. The maximum dose is reduced to 2 mg once daily for the ER capsule (or 1 mg twice daily for IR tablet) in patients with severe renal or hepatic impairment, or for those concurrently using potent CYP3A4 inhibitors. The need for continued treatment is typically re-evaluated after an initial period, such as two to three months of therapy.

Recent Clinical Evidence

Research evidence / Overview of Studies for Dextrol


Evidence for Managing Overactive Bladder (OAB) Symptoms

Dextrol was evaluated in studies for symptoms of Overactive Bladder (OAB), such as urinary urgency and frequent urination. The research comes primarily from short-term, placebo- and active-controlled Randomized Controlled Trials (RCTs). These trials were used in research exploring how symptoms change over time. The studies used standardized patient diaries to collect data on outcomes related to physical discomfort and outcomes reflecting daily functioning or activity level. Researchers monitored outcomes related to the number of times patients needed to urinate daily and the frequency of sudden, involuntary urge urinary incontinence episodes.

The short-term research, typically spanning about 12 weeks, reports how symptoms evolved in the observed adult populations. The findings describe patterns observed in the studies, including measurements related to daily voiding frequency and the volume voided per micturition (functional bladder capacity) during the study period. These research describes changes measured during the study period. Research examined Dextrol in research exploring how symptoms change over time, and studies report how symptoms evolved in the observed populations. These findings describe group patterns, not personal outcomes, and the study results reflect the specific conditions under which they were conducted.


Long-Term Data and Extended Follow-up Studies

While the core RCTs primarily focus on short-term assessment, researchers have conducted additional open-label extension studies and observations in settings evaluating daily-life functioning over longer periods. Research has explored outcomes for up to nine months and sometimes as long as two years in specific cohorts, examining outcomes reflecting daily functioning or activity level over defined time intervals. The methods for gathering data in these extended-duration studies differ from the highly controlled environment of the initial 12-week RCTs. As a result, long-term effects are not fully established under the same controlled conditions, and there is limited information for long-term outcomes beyond two years.


Understanding Evidence Gaps and Areas of Uncertainty

The most significant evidence gap is related to the data in pediatric patients. Research examined Dextrol in children with OAB; however, the findings were mixed, and the data for this group remain insufficient, indicating that the predefined study outcomes were not met in the pediatric populations studied. Additionally, comparative evidence is lacking for direct, head-to-head randomized trials comparing Dextrol against every available, newer OAB treatment. The results apply only to the populations studied, and generalization beyond the studied cohorts is uncertain.

Key Studies & References

  1. TOLTERODINE TREATMENT FOR CHILDREN WITH SYMPTOMS OF URINARY URGE INCONTINENCE SUGGESTIVE OF DETRUSOR OVERACTIVITY: RESULTS FROM (Supporting pediatric data and negative findings)

Frequently Asked Questions (FAQ)

Common questions about Dextrol (FAQ)


Q: How quickly should a person expect to notice the effects of Dextrol?

A: Official product information states that inhibitory effects on bladder function were observed within one hour following oral administration of the immediate-release form in studies with healthy volunteers. This describes the initial measurable effect on the body's systems.

Q: Does Dextrol interact with common pain relievers like ibuprofen or acetaminophen?

A: Regulatory information indicates that Dextrol can interact with many medicines. While specific common over-the-counter pain relievers may not be listed, pain medications (analgesics) that are Central Nervous System (CNS) depressants or narcotics may cause additive depressant effects. Patients are generally advised to discuss all pain relievers they use with their healthcare provider.

Q: How long does Dextrol stay in a person's system after the last intake?

A: According to clinical pharmacology data, the elimination half-life of Dextrol's active component (tolterodine) is approximately 2 to 2.4 hours for most patients. The half-life for its active metabolite is approximately 3 hours. The half-life describes the time required for the substance's concentration to be reduced by half in the body.

Q: Does Dextrol have a generic version available?

A: Yes, the active ingredient contained in Dextrol, which is tolterodine tartrate, is described in official drug listings as being available as a generic prescription medication.

Q: Is Dextrol safe to take with common vitamin or mineral supplements?

A: Official patient counseling information recommends providing your healthcare provider with a complete and accurate list of all your medications. This includes all prescription drugs, over-the-counter medicines, vitamins, nutritional supplements, and herbal products. Sharing this list helps healthcare providers consider the risk of potential interactions.

Q: Are there any known drug-herb interactions with Dextrol (e.g., St. John's Wort)?

A: Official guidance emphasizes that patients should share a complete list of all medications, including herbal products, with their provider. Some herbal products may interact with Dextrol by affecting the enzyme pathways (CYP3A4/2D6) in the body that are responsible for metabolizing the drug.

Q: Why does Dextrol need to be taken consistently to work correctly?

A: The extended-release form of Dextrol is specifically designed for once-daily administration. This is necessary to achieve and maintain continuous therapeutic levels of the active substance in the body over the full 24-hour period, supporting consistent symptom management.

Q: Can Dextrol cause changes in mood or sleep patterns?

A: Official adverse reaction reports list side effects related to mood and sleep patterns. These include insomnia (trouble sleeping), somnolence (sleepiness), and anxiety. Furthermore, post-marketing reports indicate less common events such as confusion, disorientation, and hallucinations.

Q: Can Dextrol be taken by individuals who are lactose intolerant or have specific food allergies?

A: The official regulatory profile states that Dextrol must not be used by anyone with a known hypersensitivity (allergy) to the active ingredient or any component of the formulation. The inactive ingredients list should be reviewed with a pharmacist to check for specific substances like lactose, especially for patients with known allergies or intolerances.

Q: Is Dextrol known to cause weight gain or weight loss?

A: Official documents do not list weight change as a common or frequent side effect. However, unusual weight gain or loss has been noted in post-marketing reports submitted to regulatory agencies, though the specific incidence rate is not established.

Q: What is the purpose of the 'inactive ingredients' listed in Dextrol's official documents?

A: The inactive ingredients, also called excipients, are components of the tablet or capsule that are not medically active. Their purpose is primarily functional, helping to bind the pill together, aid in the controlled delivery of the medication, and provide color and shape.

Q: Do official sources describe how Dextrol is eliminated from the body?

A: Yes, the clinical pharmacology section of official documents describes the elimination process. Following metabolism in the liver, the body recovers approximately 77% of the administered dose in the urine and about 17% in the feces.

Q: Is Dextrol mentioned as potentially interacting with caffeinated beverages?

A: Official information notes that beverages containing caffeine may aggravate underlying bladder symptoms. For this reason, consuming caffeine may affect the overall management of symptoms while taking Dextrol.

Q: Why is Dextrol considered a controlled substance (if applicable)?

A: Official drug authority records confirm that Dextrol, which contains tolterodine tartrate, is not classified as a controlled substance under federal law. It is categorized only as a prescription-only medication (Rx).

Q: Do studies show Dextrol is affected by smoking or tobacco use?

A: Official patient counseling guidelines state that individuals should inform their healthcare provider about their use of tobacco products. This information is considered relevant for assessing potential health complications when using prescription medications.

How should Dextrol be stored and disposed of?

How to Store and Dispose of Dextrol?

The storage of Dextrol (Tolterodine tartrate) must adhere strictly to official regulatory requirements to maintain its stability and ensure safety.

Storage Conditions

Requirement Official Instruction
Temperature Store at Controlled Room Temperature, 20 C to 25 C (68 F to 77 F).
Protection The product must not be frozen and must be protected from excessive heat and moisture.
Container Keep Dextrol in the original container, and ensure the container is tightly closed.
Safety The medication must be kept out of the sight and reach of children.

Disposal Instructions

Official guidance recommends the use of a formal drug take-back program for unused or expired Dextrol. If a take-back program is unavailable, the medicine should be mixed with an undesirable substance and sealed in a container before being placed in the household trash. Dextrol must not be disposed of by pouring it down a sink or toilet.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Dextrol found in:

A-Z Index: